Skip to main content
SpringerLink
Log in

Metastasiertes NSCLC ohne Plattenepithelhistologie

Nivolumab ist nach platinhaltiger Primärtherapie wirksamer als Docetaxel

  • journal club
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Brahmer J et al. N Engl J Med. 2015;373(2):123–35.

    Article  CAS  PubMed  Google Scholar 

  2. Gettinger SN et al. J Clin Oncol. 2015;33(18):2004–12.

    Article  CAS  PubMed  Google Scholar 

  3. Postow M et al. J Clin Oncol. 2015;33(17):1974–82.

    Article  CAS  PubMed  Google Scholar 

  4. Ansell SM et al. N Engl J Med. 2015;372(4):311–9.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Weber JS et al. J Clin Oncol. 2015;33(18):2092–9.

    Article  CAS  PubMed  Google Scholar 

Originalie

  • Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Freiburg, Deutschland

    Klaus Mross

Authors
  1. Klaus Mross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Mross.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mross, K. Nivolumab ist nach platinhaltiger Primärtherapie wirksamer als Docetaxel. Info Onkol. 18, 28–30 (2015). https://doi.org/10.1007/s15004-015-5167-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-015-5167-x

Schlüsselwörter

Search

Navigation